Momenta Pharmaceuticals (NASDAQ:MNTA) released third-quarter earnings, but with lackluster sales of MS drug Glatopa, most of the conference call was spent on the company's future, including plans for its immune drugs M281 and M254, which it went over at its R&D dayin October.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,